Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: NorvégiaFázis nélkül

Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism

A legfontosabb adatok

Ki végzi
Haukeland University Hospital
Hol
Bergen (Norvégia)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
60 fő, tervezett
Kezdés
2022. jún. 3.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation
  • EUS-RFA of left adrenal tumour in PA, "debulking group"
  • EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation
  • EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, "debulking group
A regiszteradat frissítve
2026. május 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary aldosteronism (PA) or mild autonomous cortisol secretion (MACS) and a tumour in the left adrenal gland. They will have the tumour treated with heat through an endoscope (EUS-RFA).

Életkor
18 to 80 years, depending on the group: 18 to 60 years (PA one-sided group), 18 to 70 years (PA debulking group), 18 to 80 years (MACS groups).
Nem
All sexes can join.
A betegség stádiuma
PA confirmed by Endocrine Society PA Guideline criteria, or MACS confirmed by ENSAT/ECE Guideline criteria. Groups: PA with extra aldosterone from the left adrenal; PA suspected mainly on the left; MACS with extra cortisol from the left adrenal and a left tumour on CT; or MACS with extra cortisol from both adrenals and tumours or enlargement on both sides on CT. A nodule seen on CT in the same adrenal must be smaller than 4 cm (1,6 in) and look like a harmless adenoma.
Biomarker vagy leletérték
PA one-sided group: adrenal vein sampling (AVS) shows the left side (lateralisation index ≥ 4,0). MACS groups: AVS shows the left side, or both sides. CT nodule features: native hounsfield units < 10 or relative wash-out > 40% or absolute wash-out > 60%.

A részvétel fő kizáró okai

  • CT scan raises suspicion of adrenal cancer.
  • Refusing to have either EUS-RFA or adrenal gland removal surgery.

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed written informed consent
  • If CT scan shows an adrenal nodule to the same adrenal as AVS lateralisation result: nodule size < 4 cm and enhancement criteria for adrenal adenoma (native hounsfield units < 10 or relative wash-out > 40% or absolute wash-out > 60%); PA unilateral group inclusion criteria:
  • Age 18 to 60 years
  • PA diagnosis confirmed according to Endocrine Society PA Guideline criteria
  • AVS lateralisation to left adrenal (lateralisation index ≥ 4,0); PA "debulking" group inclusion criteria:
  • Age 18 to 70 years
  • PA diagnosis confirmed according to Endocrine Society PA Guideline criteria; MACS unilateral and debulking group inclusion criteria:
  • Age 18 to 80 years
  • MACS diagnosis confirmed according to ENSAT/ECE Guideline criteria
  • AVS lateralisation to the left adrenal, and visible left adrenal tumor on CT scan OR bilateral overproduction of cortisol on AVS, and bilateral tumors/hyperplasia on CT scan (debulking)

Ki nem vehet részt

  • CT scan suspicion of adrenal malignancy
  • Patient refusal to undergo either EUS-RFA or adrenalectomy

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Norvégia.

  • Haukeland University HospitalBergen, NorvégiaContact: Marianne Grytaas, MD phdRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study groups will all receive EUS-RFA of left-sided adrenal tumours. Clinical and biochemical outcome as well as procedural safety will be evaluated. In study patients with verified lateralised aldosterone or cortisol overproduction to the left adrenal, outcome will be compared with control groups performing conventional unilateral adrenalectomy.

A teljes eredeti leírásKevesebb

Study group 1: PA patients with AVS-verified left sided lateralisation and a EUS-detectable tumour in the left adrenal for EUS-RFA treatment.

Study group 2: PA patient with suspected left-sided overweight of aldosterone production and a EUS-detectable tumour but without strict lateralisation of their aldosterone overproduction, for EUS-RFA treatment as an aldosterone "debulking" procedure.

Study group 3: patients with MACS with AVS-verified lateralisation of cortisol overproduction to the left adrenal and EUS-detectable tumour for EUS-RFA treatment Study group 4: patients with MACS with bilateral adrenal tumours and verified bilateral overproduction of cortisol for EUS-RFA treatment as a cortisol "debulking" procedure.

A vizsgálat 4 csoportja

  • EUS-RFA of PA with AVS-verified left lateralisationA vizsgált kezelés

    PA patients with AVS-confirmed lateralisation to the left adrenal and signed study consent will be included in this study group. EUS will be performed. If EUS identifies an adrenal nodule in the left adrenal, EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure will be performed. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.

    Kezelés: EUS-RFA of left adrenal tumour in PA with AVS-verified left lateralisation

  • EUS-RFA of PA without verified left lateralisation, for aldosterone "debulking"A vizsgált kezelés

    PA patients with suspicion of aldosterone overproduction in their left adrenal, but without fulfilling the strict AVS lateralization criteria, either due to a non-representative AVS, or a representative AVS but without significant left-sided lateralization (LI \< 4), and where the study investigators consider EUS-RFA treatment as an aldosterone-reducing procedure to be of high potential clinical and biochemical benefit for the patient, will be included in this study group after signed consent. EUS will be performed. If EUS identifies an adrenal nodule in the left adrenal, an EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.

    Kezelés: EUS-RFA of left adrenal tumour in PA, "debulking group"

  • EUS-RFA of MACS with left lateralisation and left adrenal tumourA vizsgált kezelés

    MACS patients with AVS-confirmed lateralisation the left adrenal gland and CT showing left-sided tumour will be included in this study group after signed consent. EUS will be performed, and a EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.

    Kezelés: EUS-RFA of left adrenal tumour in MACS with AVS-verified left lateralisation

  • EUS-RFA of MACS with bilateral cortisol overproduction and bilateral tumoursA vizsgált kezelés

    MACS patients with AVS-confirmed bilateral cortisol overproduction and bilateral tumours will be included in this study group after signed study consent. EUS will be performed, and EUS-guided fine needle tissue sampling of the adenoma will be performed, before a subsequent EUS-RFA treatment procedure. Follow-up after 2 weeks, 3 months and 12 months for evaluation of clinical and biochemical outcome, and procedural complications.

    Kezelés: EUS-RFA of left adrenal tumour in MACS with bilateral overproduction, "debulking group

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Endoscopic Ultrasound-guided Radiofrequency Ablation as a Novel Treatment Option Compared With Adrenalectomy in Left-sided Primary Aldosteronism
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT05368090: ki vehet részt
A regiszteradat frissítve
2026. május 8.